Keshtgar Alireza S, Ward Harry C, Sanei Ahmad, Clayden Graham S
Department of Pediatric Surgery, Guy's and St Thomas' Hospital, National Health Service Foundation Trust, SE1 9RT London, United Kingdom.
J Pediatr Surg. 2007 Apr;42(4):672-80. doi: 10.1016/j.jpedsurg.2006.12.045.
Myectomy of the internal anal sphincter (IAS) has been performed on some children after failure of medical treatment to treat idiopathic constipation. The aim of this study was to compare botulinum toxin injection with myectomy of the IAS in the treatment of chronic idiopathic constipation and soiling in children.
This was a double-blind randomized trial. Patients between 4 and 16 years old were included in the study if they had failed to respond to laxative treatment and anal dilatation for chronic idiopathic constipation. All study patients had anorectal manometry and anal endosonography under ketamine anesthesia. Outcome was measured using a validated symptom severity (SS) scoring system, with scores ranging from 0 to 65.
Of 42 children, 21 were randomized to the botulinum group and 21 were randomized to the myectomy group. At the 3-month follow-up, the median preoperative SS score improved from 34 (range = 19-47) to 20 (range = 2-43) in the botulinum group (P < .001) and from 31 (range = 18-49) to 19 (range = 3-47) in the myectomy group (P < .002). At the 12-month follow-up, the scores were 19 (range = 0-45) and 14.5 (range = 0-41) for the botulinum group and the myectomy group, respectively (P < .0001). There was no complication in both groups.
Botulinum toxin is equally effective as and less invasive than myectomy of the IAS for chronic idiopathic constipation and fecal incontinence in children.
对于一些经药物治疗无效的特发性便秘患儿,已实施了肛门内括约肌(IAS)切除术。本研究的目的是比较肉毒杆菌毒素注射与IAS切除术在治疗儿童慢性特发性便秘和大便失禁方面的效果。
这是一项双盲随机试验。年龄在4至16岁、对慢性特发性便秘的泻药治疗和扩肛治疗无反应的患者纳入本研究。所有研究患者在氯胺酮麻醉下进行肛门直肠测压和肛门腔内超声检查。使用经过验证的症状严重程度(SS)评分系统进行结果测量,评分范围为0至65。
42名儿童中,21名被随机分配至肉毒杆菌毒素组,21名被随机分配至切除术组。在3个月的随访中,肉毒杆菌毒素组术前SS评分中位数从34(范围=19 - 47)改善至20(范围=2 - 43)(P <.001),切除术组从31(范围=18 - 49)改善至19(范围=3 - 47)(P <.002)。在12个月的随访中,肉毒杆菌毒素组和切除术组的评分分别为19(范围=0 - 45)和14.5(范围=0 - 41)(P <.0001)。两组均无并发症发生。
对于儿童慢性特发性便秘和大便失禁,肉毒杆菌毒素与IAS切除术效果相当,但侵入性更小。